by Leslie Small
On Sept. 17, the U.S. Department of
Justice (DOJ) formally approved Cigna Corp.’s acquisition of Express Scripts
Holding Co., a move that sets the companies on a path to close their
transaction by the end of the year. The deal still must get the green light
from some state regulators, but industry analysts largely expect them to fall
in line with the DOJ’s verdict.
Once their tie-up is completed, though, Cigna and Express
Scripts will be tasked with a new set of challenges — including integrating two
very different businesses and creating a convincing value proposition to
clients facing a dynamic PBM landscape, experts tell AIS Health.
“I think the greatest challenge will be kind of the integration
of different cultures,” says Brian Anderson, a principal at Milliman, Inc.,
noting that Express Scripts is used to functioning as a stand-alone PBM and
Cigna as a health insurer.
But James Burns, a health care antitrust attorney and partner at
Akerman LLP, says he isn’t sure that integrating cultures will be much of an
issue for the two companies.
“In this particular merger, because the parties are in distinct
practice areas — one’s a PBM and one’s a health insurer — there won’t be,
presumably, as much of a need for wholesale integration,” he says. “I would
imagine that the PBM arm would continue to act as a PBM, and the insurer will
continue to act as an insurer, and presumably, as well, the upper level
management of the PBM wouldn’t presume to know the best way of running an
insurer and vice versa.”
PBMs of all varieties, meanwhile, are facing heightened
political scrutiny of their business model and potential changes in the
structure of prescription drug rebates. Yet Anderson says he isn’t especially
worried about those possible headwinds.
“I don’t see much of a major impact, [but] they’re going to have
to learn how to compete and learn how to fine-tune their marketing pitch,” he
says of Express Scripts and Cigna.
Subscribers may read the in-depth article online. Learn more about subscribing to AIS Health's
publications.
No comments:
Post a Comment